1. Home
  2. ATHA

as of 12-12-2025 1:08pm EST

$3.92
$0.03
-0.76%
Stocks Health Care Medicinal Chemicals and Botanical Products Nasdaq

Athira Pharma Inc is a late clinical-stage biopharmaceutical company focused on developing small molecules engineered to restore neuronal health and slow neurodegeneration. Its pipeline candidates are; Fosgonimeton (ATH-1017) is a small molecule drug candidate designed to enhance the activity of the neurotrophic hepatocyte growth factor (HGF) system; ATH-1020 a novel, orally available, next-generation small molecule drug candidate designed to positively modulate the neurotrophic HGF system; ATH-1105 is a novel, orally available, next-generation, small molecule drug candidate designed to positively modulate the neurotrophic HGF system.

Chart Type:
Time Range:
Founded: 2011 Country:
United States
United States
Employees: N/A City: BOTHELL
Market Cap: 18.2M IPO Year: 2020
Target Price: N/A AVG Volume (30 days): 19.1K
Analyst Decision: N/A Number of Analysts: N/A
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: -9.66 EPS Growth: N/A
52 Week Low/High: $2.19 - $6.18 Next Earning Date: 11-06-2025
Revenue: N/A Revenue Growth: N/A
Revenue Growth (this year): N/A Revenue Growth (next year): N/A

AI-Powered ATHA Daily Prediction

Machine learning model trained on 25+ technical indicators

Updated 3 days ago

AI Recommendation

hold
Model Accuracy: 79.73%
79.73%
Confidence

Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.

Share on Social Networks: